A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate - PubMed (original) (raw)
Comparative Study
A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate
K Fotherby et al. Fertil Steril. 1980 Aug.
Free article
Abstract
PIP: 2 populations attending WHO centers, one in Sweden and one in India, participated in a comparative, pilot trial of 2 increasingly popular injectable progestin-only female contraceptives, Depo-Provera and Norigest. The purpose of the study was to assess the pharmacokinetic and pharmacodynamic properties of the 2 formulations (depot medroxyprogesterone acetate and norethisterone enanthate). Differences were found between Swedish women and Indian women in their reactions to the 2 drugs: 1) Norigest was detectable in blood samples a significantly shorter time after injection of the agent in Indian women than in Swedish women; this difference was not apparent with Depo-Provera. 2) Although there was no difference at the 2 centers in the time of ovulation return for subjects receiving Norigest, 0 of 4 Swedish women ovulated more than 156 days after Depo-Provera injection, whereas all 4 Indian women ovulated within 73 days of Depo-Provera injection; in the Swedish women, the levels of medroxyprogesterone were undetectable at time of return to ovulation, whereas Indian women had levels of .6 ng/ml when ovulation resumed. 3) In both cultures, Depo-Provera users had significantly more episodes of bleeding and spotting than Norigest users. This preliminary report emphasizes the variety of responses possible to injection of different contraceptive progestins among various populations and points to the need for further culturally comparative studies.
Similar articles
- Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R, Hales HA, Stevenson K, Hatasaka HH, Poulson AM, Jones KP, Peterson CM. Mainwaring R, et al. Contraception. 1995 Mar;51(3):149-53. doi: 10.1016/0010-7824(95)00011-x. Contraception. 1995. PMID: 7621683 - A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I, Khan AR, Jahan FA. Swenson I, et al. Contraception. 1980 Mar;21(3):207-15. doi: 10.1016/0010-7824(80)90001-3. Contraception. 1980. PMID: 6446442 Clinical Trial. - [Prolonged-action contraceptives].
Alipov VI, Korkhov VV. Alipov VI, et al. Akush Ginekol (Mosk). 1987 Sep;(9):7-8. Akush Ginekol (Mosk). 1987. PMID: 3322079 Review. Russian. - Long acting injectable hormonal contraceptives.
Fraser IS. Fraser IS. Clin Reprod Fertil. 1982 Mar;1(1):67-88. Clin Reprod Fertil. 1982. PMID: 6226351 Review.
Cited by
- Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?
Polis CB, Achilles SL, Hel Z, Hapgood JP. Polis CB, et al. Contraception. 2018 Mar;97(3):191-197. doi: 10.1016/j.contraception.2017.12.003. Epub 2017 Dec 11. Contraception. 2018. PMID: 29242082 Free PMC article. No abstract available. - HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.
Heffron R, Stalter R, Pyra M, Nanda K, Erikson DW, Hladik F, Blue SW, Davis NL, Mugo N, Kourtis AP, Lingappa JR, Baeten JM; Partners PrEP Study and Partners in Prevention HSV/HIV Transmission Study Teams. Heffron R, et al. AIDS. 2019 Mar 15;33(4):735-744. doi: 10.1097/QAD.0000000000002123. AIDS. 2019. PMID: 30585845 Free PMC article. - Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
Bunjun R, Ramla TF, Jaumdally SZ, Noël-Romas L, Ayele H, Brown BP, Gamieldien H, Harryparsad R, Dabee S, Nair G, Onono M, Palanee-Phillips T, Scoville CW, Heller KB, Baeten JM, Bosinger SE, Burgener A, Passmore JS, Jaspan H, Heffron R. Bunjun R, et al. Clin Infect Dis. 2022 Nov 30;75(11):2000-2011. doi: 10.1093/cid/ciac284. Clin Infect Dis. 2022. PMID: 35941737 Free PMC article. Clinical Trial. - The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.
Ray RM, Maritz MF, Avenant C, Tomasicchio M, Dlamini S, van der Spuy Z, Hapgood JP. Ray RM, et al. Sci Rep. 2019 Mar 13;9(1):4334. doi: 10.1038/s41598-019-40756-7. Sci Rep. 2019. PMID: 30867477 Free PMC article. - Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.
Thurman AR, Clark MR, Hurlburt JA, Doncel GF. Thurman AR, et al. Int J Womens Health. 2013 Oct 21;5:695-708. doi: 10.2147/IJWH.S34030. Int J Womens Health. 2013. PMID: 24174884 Free PMC article. Review.